Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Filings indexed 422 across all filing types
Latest filing 2025-11-10 Investor Presentation
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - 3. kvartal 2025 operasjonell oppdatering - Signifikante effekter på systemisk inflammasjon - Attachment: 20251110_ABS_Results_Q325_Presentation.pdf
Investor Presentation Classification · 100% confidence The document is a presentation titled 'Presentation of financial results; Q3 2025' for Arctic Bioscience. It contains detailed operational highlights, financial reviews, clinical trial data, and business outlooks. It is clearly an investor-facing presentation deck used to communicate quarterly performance and strategic updates, which fits the definition of an Investor Presentation.
2025-11-10 English
Arctic Bioscience - Q3 2025 Operational update - Significant results on systemic inflammation
Earnings Release Classification · 100% confidence The document is titled 'Arctic Bioscience - Q3 2025 Operational update'. It provides a summary of quarterly financial results (revenues, gross profit, EBITDA), operational highlights (clinical trial results, product development), and future outlook. It includes a link to a webcast for a Q&A session. While it contains financial data, it is structured as an initial announcement of quarterly performance rather than a full, comprehensive interim report. Therefore, it fits the definition of an Earnings Release (ER). Q3 2025
2025-11-10 English
Arctic Bioscience - 3. kvartal 2025 operasjonell oppdatering - Signifikante effekter på systemisk inflammasjon
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly operational and financial update for Arctic Bioscience for the third quarter of 2025. It contains detailed financial statements (sales, EBITDA, liquidity), management commentary on business trends, and operational highlights. It is not merely an announcement of a report, but the report itself, containing substantive financial data and analysis for an interim period. Therefore, it is classified as an Interim/Quarterly Report. Q3 2025
2025-11-10 Norwegian
Arctic Bioscience - Invitation to presentation of Q3 operational update and HeROPA-analyses results
Report Publication Announcement Classification · 100% confidence The document is an invitation to a future presentation regarding a Q3 operational update and trial results. It is short (approx. 2000 characters) and serves as an announcement of an upcoming event rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-11-07 English
Arctic Bioscience - Invitasjon til presentasjon av Q3 operasjonell oppdatering og resultater fra HeROPA-analyser
Report Publication Announcement Classification · 100% confidence The document is an invitation to a webcast presentation regarding Q3 operational updates and HeROPA study results. It is short (under 5,000 characters) and serves as an announcement for an upcoming event rather than the financial report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-11-07 Norwegian
Arctic Bioscience - Analyse av HeROPA-studien viser statistisk signifikante effekter av HRO350 på betennelse - Attachment: Attachm_Analysis_details_and_results.pdf
Investor Presentation Classification · 95% confidence The document is a presentation detailing the results of a clinical trial (HeROPA phase 2b) for a drug candidate (HRO350). It contains charts, clinical trial data (PASI, SII, PGA scores), and analysis of patient outcomes. It is explicitly labeled as an 'Attachment to stock exchange release', which confirms it is a supplementary presentation document rather than a standalone regulatory filing or a full annual report. Given its focus on clinical trial results and investor-facing data, it is best classified as an Investor Presentation. Q4 2025
2025-11-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.